Truncating ARL6IP1 variant as the genetic cause of fatal complicated hereditary spastic paraplegia.


Journal

BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552

Informations de publication

Date de publication:
04 07 2019
Historique:
received: 03 03 2019
accepted: 19 06 2019
entrez: 6 7 2019
pubmed: 6 7 2019
medline: 4 12 2019
Statut: epublish

Résumé

Mutations in ARL6IP1, which encodes a tetraspan membrane protein localized to the endoplasmic reticulum (ER), have been recently described in a large family with a complicated form of hereditary spastic paraplegia (HSP). We sought to expand the HSP phenotype associated with ARL6IP1 variants by examining a Saudi kindred with a clinically more severe presentation, which resulted in spontaneous neonatal death of both affected siblings. Clinical features encompassed not only spastic paraplegia but also developmental delay, microcephaly, cerebral atrophy, periventricular leukoencephalopathy, hypotonia, seizures, spasticity, jejunal stricture, gastrointestinal reflux, neuropathy, dysmorphism and respiratory distress. We performed clinical assessment and radiological studies of this family, in addition to homozygosity mapping and whole exome sequencing (WES) to identify the disease-associated variant. Homozygosity mapping localized the causative gene to a region on chromosome 16 harboring ARL6IP1. WES of the index case identified the homoallelic nonsense variant, c.112C > T in ARL6IP1 that segregated with the phenotype and was predicted to result in loss of the protein. Allelic expression analysis of the parents demonstrated downward pressure on the mutant allele, suggestive of nonsense-mediated decay. Our report shows that the phenotype associated with ARL6IP1 variants may be broader and more acute than so far reported and identifies fatal HSP as the severe end of the phenotypic spectrum of ARL6IP1 variants.

Sections du résumé

BACKGROUND
Mutations in ARL6IP1, which encodes a tetraspan membrane protein localized to the endoplasmic reticulum (ER), have been recently described in a large family with a complicated form of hereditary spastic paraplegia (HSP).
CASE PRESENTATION
We sought to expand the HSP phenotype associated with ARL6IP1 variants by examining a Saudi kindred with a clinically more severe presentation, which resulted in spontaneous neonatal death of both affected siblings. Clinical features encompassed not only spastic paraplegia but also developmental delay, microcephaly, cerebral atrophy, periventricular leukoencephalopathy, hypotonia, seizures, spasticity, jejunal stricture, gastrointestinal reflux, neuropathy, dysmorphism and respiratory distress. We performed clinical assessment and radiological studies of this family, in addition to homozygosity mapping and whole exome sequencing (WES) to identify the disease-associated variant. Homozygosity mapping localized the causative gene to a region on chromosome 16 harboring ARL6IP1. WES of the index case identified the homoallelic nonsense variant, c.112C > T in ARL6IP1 that segregated with the phenotype and was predicted to result in loss of the protein. Allelic expression analysis of the parents demonstrated downward pressure on the mutant allele, suggestive of nonsense-mediated decay.
CONCLUSIONS
Our report shows that the phenotype associated with ARL6IP1 variants may be broader and more acute than so far reported and identifies fatal HSP as the severe end of the phenotypic spectrum of ARL6IP1 variants.

Identifiants

pubmed: 31272422
doi: 10.1186/s12881-019-0851-6
pii: 10.1186/s12881-019-0851-6
pmc: PMC6610916
doi:

Substances chimiques

ARL6IP1 protein, human 0
Adaptor Proteins, Signal Transducing 0
Membrane Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119

Références

Science. 2014 Jan 31;343(6170):506-511
pubmed: 24482476
Exp Neurol. 2014 Nov;261:518-39
pubmed: 24954637
Am J Hum Genet. 2019 Apr 4;104(4):767-773
pubmed: 30929741
J Biol Chem. 2008 Nov 14;283(46):31323-32
pubmed: 18684713
Science. 2008 Feb 29;319(5867):1247-50
pubmed: 18309084
Clin Genet. 2018 Jan;93(1):169-172
pubmed: 28471035
Hum Mol Genet. 2016 Jul 1;25(13):2827-2837
pubmed: 27170313
Brain. 2017 Feb;140(2):287-305
pubmed: 28137957
Biochem J. 2014 Feb 15;458(1):69-79
pubmed: 24262037
J Neurol Sci. 2012 Jul 15;318(1-2):1-18
pubmed: 22554690
Eur J Hum Genet. 2017 Feb;25(2):176-182
pubmed: 27848944

Auteurs

Salma M Wakil (SM)

Department of Genetics, Research Centre, King Faisal Specialist Hospital & Research Centre, MBC-03, P.O. Box 3354, Riyadh, 11211, Saudi Arabia. smajid@kfshrc.edu.sa.
Saudi Human Genome Program, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. smajid@kfshrc.edu.sa.

Safa Alhissi (S)

Department of Genetics, Research Centre, King Faisal Specialist Hospital & Research Centre, MBC-03, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Haya Al Dossari (H)

Department of Genetics, Research Centre, King Faisal Specialist Hospital & Research Centre, MBC-03, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Ayesha Alqahtani (A)

Department of Genetics, Research Centre, King Faisal Specialist Hospital & Research Centre, MBC-03, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Sherin Shibin (S)

Department of Genetics, Research Centre, King Faisal Specialist Hospital & Research Centre, MBC-03, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Brahim T Melaiki (BT)

Prince Sultan Riyadh Military Medical City, Riyadh, Saudi Arabia.

Josef Finsterer (J)

Department of Neurology, Krankenanstalt Rudolfstiftung, Messerli Institute, Postfach 20, 1180, Vienna, Austria.

Amal Al-Hashem (A)

Prince Sultan Riyadh Military Medical City, Riyadh, Saudi Arabia.

Saeed Bohlega (S)

Department of Neurosciences, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.

Anas M Alazami (AM)

Department of Genetics, Research Centre, King Faisal Specialist Hospital & Research Centre, MBC-03, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.
Saudi Human Genome Program, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH